Dinutuximab combination therapy becomes frst approval for high-risk neuroblastoma T he approval of dinutuximab by the US Food and Drug Administration marks the third approval for a pediatric cancer and the frst for patients with high-risk neuroblastoma. 1 Dinutuximab is an immunotherapeutic agent; a monoclonal antibody (mAb) targeting a glycolipid that is highly expressed on the surface of neuroblastoma cells.
Te mAb was approved in combination with the cytokines granulocyte macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2), and the oral retinoid isotretinoin (RA). Te approval was based on a pivotal, phase 3, multicenter, open-label, randomized trial conducted by the Children's Oncology Group between October 2001 and January 2009 that was stopped early after the combination demonstrated superiority over standard therapy with respect to event-free survival (EFS). 2 Two hundred and twenty-six patients (mostly pediatric patients, though age up to 31 years at diagnosis was allowed) with high-risk neuroblastoma were enrolled based on the following criteria: age of ≤31 years at diagnosis; completion of induction therapy, autologous stem-cell transplant (SCT), and radiation therapy, with autologous SCT performed within 9 months of initiation of induction therapy; achievement of at least partial response prior to autologous SCT; enrollment between 50-100 days after fnal autologous SCT; absence of progressive disease; adequate organ function; life expectancy of at least 2 months; and prior enrollment in the COG biology study (ANBL00B1). An additional 25 patients with biopsy-proven residual disease after autologous SCT were also enrolled, but were nonrandomly assigned to the immunotherapy arm and were excluded from the primary outcome analysis. Patients with systemic infections or a requirement for concomitant systemic corticosteroids or immunosuppressant usage were ineligible.
Patients were randomized 1:1 to receive either standard RA or dinutuximab combination therapy. Tose who were randomized to the immunotherapy arm received up to 5 cycles of dinutuximab at a dose of 25 mg/m 2 body surface area [BSA] a day administered over 4 consecutive days, in addition to concurrent daily GM-CSF in cycles 1, 3, and 5 at a dose of 250 µg/m 2 a day for 14 days, starting 3 days before dinutuximab, and concurrent IL-2 in cycles 2 and 4 administered as a continuous infusion for 4 days during week 1 at a dose of 3 x 10 6 IU/m 2 a day and for 4 days in week 2 at 4.5 x 10 6 IU/m 2 a day. In both treatment arms, RA was administered at a dose of 160 mg/m 2 BSA/day, divided into 2 doses for 14 consecutive days within each of 6 consecutive 28-day cycles. Randomization was stratifed on the basis of factors thought to potentially afect postautologous SCT outcome. EFS, defned as the time from study enrollment until frst relapse, progressive disease, secondary cancer, death, Report prepared by Jane de Lartigue, PhD. JCSO 2015;13:344-346. ©2015 Frontline Medical Communications. DOI 10.12788/jcso.0172.
What's new, what's important
The US Food and Drug Administration (FDA) approved dinutuximab as part of frst-line therapy for pediatric patients with highrisk neuroblastoma.
Dinutuximab is a GD2-binding monoclonal antibody indicated, in combination with granulocyte-macrophage colonystimulating factor, interleukin-2, and 13-cis-retinoic acid for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior frst-line multiagent, multimodality therapy.
The pivotal study showed that after 3 years of follow-up, Preclinical studies suggested that combining dinutuximab with the cytokines granulocyte macrophage colony-stimulating factor and interleukin-2 could boost the ADCC activity of this mAb, which served as the rationale for analyzing this particular combination.
Mechanism of action -dinutuximab Immunotherapy targeting neuroblastoma cells
or last contact with patient, was not reached at a median of 3.4 years in the dinutuximab arm, compared with 1.9 years in the RA arm (hazard ratio [HR], 0.57; P = .01). Based on an additional 3 years of follow-up after the seventh interim analysis of EFS, median OS, defned as the time from study enrollment until death or last contact with patient was not yet reached in either the dinutuximab or RA arms, but there was a trend toward improved OS in the immunotherapy group. Te 2-year estimates for EFS and OS were 66% and 86%, respectively, in the dinutuximab arm, compared with 46% and 75% in the RA arm (P = .01 and .02, respectively).
Most of the patients (80%) were aged ≥1 year and had International Neuroblastoma Staging System stage 4 disease at the time of diagnosis. Within this subgroup of patients, EFS was 63% vs 42% in the dinutuximab and RA groups, respectively, and OS was 84% vs 76%. Among the 25 patients who were nonrandomly assigned to immunotherapy, the 2-year estimates were 36% for EFS and 76% for OS over a median follow-up of 3.6 years.
Stage 4 disease was predictive of lower EFS and diploidy (normal tumor cell DNA index) was predictive of worse OS. Meanwhile, complete or very good partial response prior to autologous SCT was predictive of both improved EFS and OS. No other factors among the 9 assessed were signifcantly predictive of outcome.
Te safety of dinutuximab in patients with high-risk neuroblastoma has been evaluated in 1,021 patients, including both the pivotal trial and 2 single-arm clinical trials. Tere was an increased incidence of treatment-related adverse events (AEs) in the dinutuximab arm, though the toxic efects were mostly expected and attributable to the binding of the antibody to GD2 on normal nerve cells or to cytokine activity. Most commonly, patients treated with dinutuximab experienced pain, pyrexia, thrombocytopenia, lymphopenia, infusion reactions, hypotension, capillary leak syndrome, and hypersensitivity reactions. Te most common serious AEs were infections, infusion reactions, hypokalemia, hypotension, pain, fever and capillary leak syndrome. In the pivotal trial, grade 3/4 pain was experienced by 51% of patients and was reported as a serious AE in 6%, most commonly in the abdomen and during cycle 1. Capillary leak syndrome occurred in 23% of patients, most frequently during cycles 2 and 4 involving IL-2. Grade 3/4 hypersensitivity reactions afected a quarter of patients and were also more frequent in cycles involving IL-2.
Per the prescribing information, the approved dose of dinutuximab is 17.5 mg/m 2 a day as a diluted intravenous infusion over 10-20 hours for 4 consecutive days for up to 5 cycles. 3 Te initial infusion rate should be 0.875 mg/m 2 an hour, gradually increasing as tolerated to a maximum of 1.75 mg/m 2 an hour. Patients should receive pretreatment with intravenous hydration, analgesics, antihistamines, and antipyretics prior to initiation of dinutuximab, according to the guidelines laid out in the prescribing information, to help guard against some of the toxic efects of the drug.
Dinutuximab, which is marketed as Unituxin by United Terapeutics Corporation, comes with a boxed warning against infusion reactions, including facial and upper airway edema, dyspnea, bronchospasm, stridor, urticaria, and hypotension, and neuropathy, including severe neuropathic pain, peripheral sensory neuropathy, and motor neuropathy, to alert patients and healthcare providers to these potentially severe side efects. Other warnings and precautions detail the risks of capillary leak syndrome, hypotension, neurological disorders of the eye, bone marrow suppression, electrolyte abnormalities, and atypical hemolytic uremic syndrome. Te prescribing information guides dose modifcation in the case of some of these adverse events. Patients should also be monitored for signs and symptoms of infusion reactions and systemic infections, as well as have blood pressure and peripheral blood counts checked regularly. Pregnant women should be advised of the potential risk to the fetus and the need for efective contraception during and for 2 months after treatment. Dinutuximab has not yet been studied in patients with renal or hepatic impairment.
